Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o. — Clinical Trial Site

67 Registered trials

31 Currently recruiting

Organisation

Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.

Location

Siedlce, Poland

Identifier

ORG-100043855

Address

Ul. Ksiecia Jozefa Poniatowskiego 26, 08-110, Poland

Departments

Bodnar Oddział Onkologii Klinicznej i Radioterapii
Department of Obstetrics, Gynecology and Gynecological Oncology
n/a
Oddzial Kardiologiczny
Oddzial Onkologii Klinicznej i Radioterapii
Oddział Onkologii Klinicznej i Radioterapii
Oddział Onkologii Klinicznej i Radioterapii Zakład Radioterapii
Oddział Onkologii Klinicznej i Radioterapii, Siedleckie Centrum Onkologii
Oncology
Siedleckie Centrum Onkoligii Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii
Siedleckie Centrum Onkologii Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii (SCO)
Siedleckie Centrum Onkologii OddziaL Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii,
Siedleckie Centrum Onkologii, Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii, Oddzial Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii, Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii, Oddział Onkologii Klinicznej i Radioterapii
Siedleckie Centrum Onkologii; Oddział Onkologii Klinicznej i Radioterapii

Clinical trials at this site (67)

Search interface

A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Metastatic Colorectal Cancer 5 2022-12-22
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended

2023-506361-56-00 Endometrial cancer 5 2022-04-01
A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended

2024-512148-50-00 Non-small cell lung cancer 5 2022-03-03
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended

2023-505615-21-00 Muscle Invasive Bladder Cancer 5 2021-04-28
Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Muscle Invasive Bladder Cancer 11 2020-03-17
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Endometrial cancer 5 2020-01-30
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended

2023-506092-10-00 Stage III-IVA Resectable Locoregionall Advanced Head an 4 2024-03-11
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended

2022-502453-33-00 Advanced Endometrial Cancer 4 2024-02-26
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian… Ended

2023-505005-16-00 Primary peritoneal cancer/Fallopian tube cancer 4 2022-07-27
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Solid tumours 9 2022-06-29